Stem Cell Therapy Market Size will Reach USD 31.41 Billion by 2030

According to Precedence Research, during the forecast period of 2022 to 2030, the global stem cell therapy market is estimated to develop at a compound annual growth rate (CAGR) of 13.73%. The global stem cell therapy market was valued at USD 9.87 billion in 2021, and it is predicted to exceed USD 31.41 billion by 2030. The study investigates several elements and their consequences on the growth of the stem cell therapy market.

Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1989

This report focuses on stem cell therapy market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall stem cell therapy market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.

Report Scope of the Stem Cell Therapy Market

The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

In-Depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of stem cell therapy, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of stem cell therapy has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the stem cell therapy market.

Some of the prominent players in the stem cell therapy market include:

• Caladrius
• CELGENE CORPORATION
• ReNeuron Group plc
• Virgin Health Bank
• Opexa Therapeutics, Inc.
• Pluristem Therapeutics Inc
• STEMCELL Technologies Inc.
• Biovault family
• Precious Cells International Ltd
• Mesoblast Ltd
• Seneca Biopharmaceuticals, Inc.

Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1989

Segments Covered in the Report

By Product

• Adult Stem Cells (ASCs)
  • Hematopoietic
  • Mesenchymal
  • Neural
  • Epithelial/Skin
  • Others
• Human Embryonic Stem Cells (HESCs)
• Induced Pluripotent Stem Cells (iPSCs)
• Very Small Embryonic Like Stem Cells

By Therapy Type

• Autologous
• Allergenic

By Application

• Regenerative Medicine
  • Neurology
  • Orthopedics
  • Oncology
  • Hematology
  • Cardiovascular and Myocardial Infraction
  • Injuries
  • Diabetes
  • Liver Disorder
  • Incontinence
  • Others
• Drug Discovery and Development

By Technology

• Cell Acquiition
  • Bone Marrow Harvest
  • Umbilical Blood Cord
  • Apheresis
• Cell Production
  • Therapeutic Cloning
  • In-vitro Fertilization
  • Cell Culture
  • Isolation
• Cryopreservation
• Expansion and Sub-Culture

By End User

• Hospitals
• Research institutes
• surgical institutes
• Orders

Regional Segmentation

• Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
• Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
• North America [United States, Canada, Mexico]
• South America [Brazil, Argentina, Columbia, Chile, Peru]
• Middle East & Africa [GCC, North Africa, South Africa]

Some of the important ones are:

• What can be the best investment choices for venturing into new product and service lines?
• What value propositions should businesses aim at while making new research and development funding?
• Which regulations will be most helpful for stakeholders to boost their supply chain network?
• Which regions might see the demand maturing in certain segments in near future?
• What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
• Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
• Which government regulations might challenge the status of key regional markets?
• How will the emerging political and economic scenario affect opportunities in key growth areas?
• What are some of the value-grab opportunities in various segments?
• What will be the barrier to entry for new players in the market?

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Stem Cell Therapy Market 

5.1. COVID-19 Landscape: Stem Cell Therapy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Stem Cell Therapy Market, By Product

8.1. Stem Cell Therapy Market, by Product, 2022-2030

8.1.1. Adult Stem Cells (ASCs)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Human Embryonic Stem Cells (HESCs)

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Induced Pluripotent Stem Cells (iPSCs)

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Very Small Embryonic Like Stem Cells

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Stem Cell Therapy Market, By Therapy Type

9.1. Stem Cell Therapy Market, by Therapy Type, 2022-2030

9.1.1. Autologous

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Allergenic

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Stem Cell Therapy Market, By Application 

10.1. Stem Cell Therapy Market, by Application, 2022-2030

10.1.1. Regenerative Medicine

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Drug Discovery and Development

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Stem Cell Therapy Market, By Technology

11.1. Stem Cell Therapy Market, by Technology, 2022-2030

11.1.1. Cell Acquiition

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cell Production

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Cryopreservation

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Expansion and Sub-Culture

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Stem Cell Therapy Market, By End User

12.1. Stem Cell Therapy Market, by End User, 2022-2030

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Research institutes

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. surgical institutes

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Orders

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Stem Cell Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.7.  Rest of North America

13.1.7.1.  Market Revenue and Forecast, by Product (2017-2030)

13.1.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.1.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.1.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.7.  Germany

13.2.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.7.3.  Market Revenue and Forecast, by Application (2017-2030)

13.2.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.2.8.  France

13.2.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.8.5.  Market Revenue and Forecast, by End User (2017-2030)

13.2.9. Rest of Europe

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.2.9.5.  Market Revenue and Forecast, by End User (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.6.  India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.7. China

13.3.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.7.2.  Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.8. Japan

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2.  Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.3.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.3.9.5. Market Revenue and Forecast, by End User (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.6.3.  Market Revenue and Forecast, by Application (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.7. North Africa

13.4.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.7.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.8. South Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.9. Rest of MEA

13.4.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.9.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.4.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.9.4. Market Revenue and Forecast, by Technology (2017-2030)

13.4.9.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.  Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.6.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.7. Rest of LATAM

13.5.7.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)

13.5.7.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.7.4. Market Revenue and Forecast, by Technology (2017-2030)

13.5.7.5. Market Revenue and Forecast, by End User (2017-2030)

Chapter 14. Company Profiles

14.1. Caladrius

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. CELGENE CORPORATION

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. ReNeuron Group plc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Virgin Health Bank

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Opexa Therapeutics, Inc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Pluristem Therapeutics Inc

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. STEMCELL Technologies Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Biovault family

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Precious Cells International Ltd

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Mesoblast Ltd

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1989

About Us

Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.

From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.

Contact Us:                  

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com